POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Canada not to use 300,000 doses of Johnson & Johnson vaccine due to possible quality issue

Christian Fernsby |
Health Canada said Friday it will not release the 300,000 Johnson & Johnson COVID-19 vaccine doses which arrived in Canada in April due to a possible quality issue.

Article continues below




"To protect the health and safety of Canadians in response to concerns regarding a drug substance produced at the Emergent BioSolutions facility in Baltimore Maryland, Health Canada will not be releasing the shipment," the government department said in a statement.

The drug substance produced at the facility was used in the manufacturing of this shipment of Janssen vaccines.

"The drug substance was manufactured at the time a separate batch of vaccines was contaminated by the components of a different vaccine. Health Canada was unable to determine that this shipment of Janssen vaccines meets the Department's rigorous quality standards," said the statement.

To ensure the safety of any future vaccine supply from this facility, Health Canada is planning an onsite inspection, expected to take place this summer.

"Until this inspection has been completed, Canada will not be accepting any product or ingredients made at this site," it said.

The statement came after the U.S. Food and Drug Administration (FDA) said Friday that Johnson & Johnson must throw away millions of doses of its COVID-19 vaccine that were manufactured at the Baltimore facility.

The FDA halted production of the Johnson & Johnson vaccine at the Baltimore site after discovering that ingredients from AstraZeneca's COVID-19 vaccine also being produced at the plant at the time contaminated a batch of Johnson & Johnson vaccine.

An FDA inspection also reportedly found sanitary problems and bad manufacturing practices at the plant.

AstraZeneca's shot is no longer being made at the Baltimore facility, and Health Canada previously said that the 1.5 million doses of AstraZeneca vaccine it had imported from this facility were safe and met quality specifications.


What to read next

FDA extends shelf life of Johnson & Johnson COVID-19 vaccine amid expiration controversy
Canada secures vaccine supply beyond 2021
Preteens need only 2 HPV shots—not 3, panel says